Finkelstein and colleagues reported that high DC/MDSC ratios and low pretreatment MDSC levels could predict response to high-dose IL-2 therapy in patients with melanoma and renal cell carcinoma [39]. This evidence concerns the gene IL2 and renal cell carcinoma.